Lifeboat Foundation

(https://hannalabweb.weizmann.ac.il/) is a Senior Scientist and Professor in the Department of Molecular Genetics at the Weizmann Institute of Science in Israel, where his lab, and the interdisciplinary group of scientists within it, are focused on understanding the complexity of early embryonic stem cell biology and early developmental dynamics, as well as advancing human disease modeling.

More specifically, Dr. Hanna’s lab investigates the detailed process of cellular reprogramming, in which induced pluripotent stem cells are generated from somatic cells, and they investigate how pluripotency is maintained throughout development in mouse and human. In their studies they employ a diverse arsenal of biological experimentation methods, high throughput screening, advanced microscopy and genomic analyses seeking to combine biological experimentation with computational biology, theory and modeling, to elucidate various biological questions.

Continue reading “Dr. Jacob Hanna, MD, Ph.D. — Synthetic Embryo R&D In Regenerative Medicine & Developmental Biology” »

Mount Sinai researchers have cataloged thousands of sites in the brain where RNA is modified throughout the human lifespan in a process known as adenosine-to-inosine (A-to-I) editing, offering important new avenues for understanding the cellular and molecular mechanisms of brain development and how they factor into both health and disease.

In a study published in Cell Reports, the team described how the rate of RNA editing in the brain increases as individuals age, with implications for dissecting the pathology of altered A-to-I editing across a range of neurodevelopmental and aging disorders.

“Our work provides more nuanced and accurate insights into the contribution of RNA modifications by A-to-I editing during human brain development,” says senior author Michael Breen, Ph.D., Assistant Professor of Psychiatry, and Genetics and Genomic Sciences, at the Icahn School of Medicine at Mount Sinai, and a member of the Seaver Center for Autism Research and Treatment.

Researchers from North Carolina State University have developed a new method for determining which genes are relevant to the aging process. The work was done in an animal species widely used as a model for genetic and biological research, but the finding has broader applications for research into the genetics of aging.

“There are a lot of genes out there that we still don’t know what they do, particularly in regard to aging,” says Adriana San Miguel, corresponding author of a paper on the work and an assistant professor of chemical and biomolecular engineering at NC State.

That’s because this field faces a very specific technical challenge: by the time you know whether an organism is going to live for a long time, it’s old and no longer able to reproduce. But the techniques we use to study genes require us to work with animals that are capable of reproducing, so we can study the role of specific genes in subsequent generations.

Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD

TruDiagnostic Discount Link (Epigenetic Testing)
CONQUERAGING!
https://bit.ly/3Rken0n.

Continue reading “Dietary Fiber And SCFAs Are Relatively Higher in Centenarians-A Pathway To Longevity?” »

Do you want to live a better, healthier and longer life? Me too.

Lets go back to 1937, when Albert Szent-Györgyi won a Nobel Prize for his discovery of ascorbic acid—vitamin C—that enables the body to efficiently use carbohydrates, fats, and protein (I use it a lot during cold and flu season, you?). It was a massively consequential discovery, as it not only saved and extended countless lives, but it also contributed to the foundations of modern nutrition. Szent-Györgyi, himself, was blessed with a long life; he died in 1986 at the age of 93. But he might just as well be known for what he said on his 90th birthday: “I wish I could be 75 again!”

No doubt, that comment elicits more than a few eyerolls today. Especially since the CDC has recently downgraded American life expectancy to just 77 years. But could 75 someday be the new 40—an age by which, like Szent-Györgyi, we’re only hitting our stride? Well, if the burgeoning activity of the life extension industry is any indication, we may actually be on the cusp of making it so—and enjoying life to the fullest right up to the extended end. Which brings us to the morbid thought of mortality—that end state most of us seek to delay, if not dodge.

Newswise — LOS ANGELES (Oct. 28, 2022) — Cedars-Sinai has been awarded a five-year, $8 million grant from California’s stem cell agency to launch an innovative new clinic that will expand patients’ access to stem cell and gene therapies, increase research and training in regenerative medicine, foster greater collaboration with eight similar clinics across the state and help educate the public about stem cell and related therapies.

The California Institute for Regenerative Medicine (CIRM) approved Cedars-Sinai’s plan to establish an Alpha Stem Cell Clinic, bringing Cedars-Sinai into a network of Alpha sites throughout California. The Cedars-Sinai clinic will develop preclinical studies into early and later phase clinical trials with the goal of establishing advanced regenerative medicine treatments that are FDA-approved for patients with debilitating diseases.

The Cedars-Sinai initiative is being led by the Cedars-Sinai Board of Governors Regenerative Medicine Institute and the Smidt Heart Institute. They are modeling the new Alpha Clinic on a jointly run Regenerative Medicine Clinic established at Cedars-Sinai in 2014—expanding scientific discovery and clinical trials for neurological, cardiovascular, musculoskeletal and autoimmune diseases.

It was in 1975 when scientists from Ayerst (now Pfizer) discovered a novel compound called rapamycin (also known as Sirolimus) in bacteria on Rapa Nui(Easter Island) in Chile. In 1999 rapamycin obtained FDA approval for the prevention of acute rejection of renal transplant. Unknown at the time, rapamycin would become the most potent anti-aging drug that humans currently hold.

This is the first article of a two-part series on rapamycin.

The profound effect rapamycin has on lifespan was first observed in yeast cells, and later confirmed in every model organism tested, including the nematode C. elegans, fruit flies, and mice.

To test the interaction between senolytic removal of senescent cells and cellular reprograming, we designed a model combining these two interventions in an inducible overexpression system in Drosophila. First, we used the four Yamanaka factor based OKSM approach as this had been previously shown to induce pluripotent stem cells in mice [7], humans [29 – 31] and non-mammalian vertebrate and invertebrate species [32]. To make a senolytic factor for Drosophila, we took advantage of the mouse sequence (FOXO4-DRI [22]) to design an orthologous peptide based on the Drosophila foxo (forkhead box, sub-group O) gene [33]. We then characterized effects of these two interventions independently as well as in combination.

We began by looking at the effect of OKSM and Sen on stem cells in an intestinal stem cell (ISC) model [34, 35]. We chose to investigate phenotypic effects specifically in the digestive system of Drosophila (Supplementary Figure 1). As in mammals, the Drosophila gastric lining has a high turnover of cells which is enabled by stem cell pools that replenish the epithelia [34]. Age-dependent loss of stem cells and degradation of barrier function has been shown to contribute to age-dependent functional decline and mortality in Drosophila [36]. The Drosophila gut is composed of four cell types: enterocytes (ECs or absorptive cells), enteroendocrine (EEs or secretory cells), enteroblasts (EBs or transit amplifying cells) and intestinal stem cells (ISCs).

When we think about aging, one of the first thoughts that comes to mind is wrinkled and sagging skin as well as the greying and loss of hair – simply put, the physical changes to appearance that we associated with advancing age. These changes are the most striking reflection of the underlying molecular aging processes that are happening inside our bodies.

The current size of the cosmetic industry alone highlights that physical appearance is important to people. As we continue developing strategies to improve longevity allowing us to live longer and in far better health, people will inevitably want a “youthful appearance” to match their newfound “youthful state”. Furthermore, as this report explains in more detail, aesthetic aging plays a significant and grossly underappreciated role in influencing the rate of biological aging.

It is fair to say that the cosmetic industry alone might not be enough to address aesthetic aging from a longevity point of view, as cosmetic products work to conceal the signs of aging. We need tactics that can address the underlying causes of skin and hair aging to achieve long-term benefits and halt the fine interlink between aesthetic aging and biological aging. This is where advanced aesthetics comes in.